Gpr35 Expression Mitigates Neuroinflammation and Enriches Gut to Relieve Parkinson's Disease.

Parkinson's disease (PD) is associated with gut-brain axis and gut microbiota alterations, but the functioning mechanism remains to be elucidated. In this study, we identified G protein-coupled receptor 35 (Gpr35) as a key regulator for the gut-brain association under the PD context. It investigated the impact of Gpr35 deficiency on motor function, neuroinflammation, and dopaminergic neurodegeneration, using the Gpr35 knockout (Gpr35) and wild-type (WT) mice in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model, and Gpr35 up-/down-regulation on reverse neuroinflammation, oxidative stress, and neuronal apoptosis using Gpr35 agonist kynurenic acid (KYNA) and small interfering RNA in microglial and dopaminergic cell models. It was confirmed that Gpr35 may prevent PD by modulating neuroinflammation and gut microbiota and metabolite composition, specifically through enriching , and substantially regulating tyrosine metabolism, neuroactive ligand-receptor interaction, and tryptophan metabolism pathways, thereby inhibiting the progression of PD. Our findings highlight the potential of targeting Gpr35 to influence both the gut microbiota and central nervous system, offering new insights into the treatment of PD.